Staked INJ ETF: What Nasdaq Access and Europe’s MiCA Filing Could Mean Injective’s native token is opening two doors at once. In the United States, the Canary Staked INJ ETF, ticker INJC, beg
Injective’s native token is opening two doors at once. In the United States, the Canary Staked INJ ETF, ticker INJC, began trading on Nasdaq in November 2026.
In Europe, the project has published a MiCA white paper that sits sits in the regulator’s public register.
Canary Capital, a digital asset investment firm, announced the launch of INJC on November 5, 2026, in itsofficial launch announcement.
The fund trades on Nasdaq (see theexchange’s INJC page) and aims to follow the price of INJ, the native token of the Injective blockchain.
Its inception date is November 4, 2026, according to the official fund page.
Canary calls it the first US spot fund of its kind. Injective’s own launch post says co-founder Eric Chen sees it as a way for investors to reach the asset through brokerage accounts they already use.
The announcement also shares network figures:
Over 3.13 billion transactions processed as of October 22, 2026
Over 7.27 million tokens (about $58 million) permanently removed through monthly buybacks
Over $1 billion in assets tokenized, as of October 2026
Over $25 million of native USDC issued on the network as of October 2026
The fund holds the token directly, so its value follows the token’s price, minus the fund’s costs.
It also aims to earn extra tokens through “staking”, which means locking tokens to help the network check transactions in return for rewards.
Per the launch announcement, net staking rewards are reflected in the fund’s net asset value (NAV), which is the per-share value of everything the funds hold.
The fund-page adds that staking rewards are not paid to investors directly.
The fund-does not run a validator itself. The sponsor manages staking through service providers.
The fund-page lists BitGo Bank & Trust as digital asset custodian, Luganodes as staking provider, and U.S. Bank as cash custodian and administrator.
Shares trade at market price, not NAV, and investors need no wallet or private keys.
These figures come from theofficial fund page, as of November 11, 2026:
Item
Figure
Market price
$25.16
NAV per share
$25.12
Premium to NAV
0.15%
30-day spread
0.31%
Net assets
About $15.07 million
Sponsor fee
1.10%
Daily volume
2,313 shares
Share of assets staked
100%
Return since inception
NAV 0.48%, market price 0.64%
The premium shows how far the market price sits above NAV. The spread is the gap between buying and selling prices.
Staking yield figures were not yet shown on the page. With only about a week of history, it is too early to judge performance.
Injective’sofficial blog says INJ’sMiCA white paper was published and listed in theESMA Interim MiCA Register.
MiCA is the EU’s Markets in Crypto-Assets Regulation. Denmark is the home Member State, and the document is passported across the other 29 EEA countries, so one public record covers 30 markets.
The Injective Foundation filed it for admission to trading. It is not a new public offering, and no funds are being raised.
The white paper records:
How fees, staking and governance work
The Community BuyBack, where committed tokens are permanently burned
Holder responsibilities, supply and technical design
Risks
The same post is clear about limits. No platform had confirmed admission when it was published, each venue makes its own listing decision, and no EU authority has endorsed the asset.
This is a path to access, not a guaranteed listing.
Date
Step, per official sources
April 15, 2026
Bitnomial launches the first US-regulated INJ futures
June 25, 2026
Canary files an amended preliminary registration statement
July 16, 2026
Injective blog announces the MiCA white paper
November 5, 2026
INJC launch announced
The issuer’s disclosures are direct about risk. Anyone considering the Staked INJ ETF should read the prospectus first.
Key points:
The fund is not registered under the Investment Company Act of 1940, so it lacks that Act’s protections.
It is not a direct investment in the token, and the whole investment can be lost.
Staking rewards are not guaranteed and may fall.
Staked tokens can face “slashing” penalties, which are losses for validator faults.
Assets are not covered by FDIC or SIPC protection.
The fund is new, with limited history.
Worth watching next are the fund’s staking yield figures, net assets and trading volume, and whether any European platform confirms admission. Injective’sofficial X account has highlighted both steps.
The Staked INJ ETF gives US investors a brokerage route to the token with staking built in, while the MiCA white paper gives European platforms a standard public record to review.
Neither step guarantees demand or listings, and the early numbers are small. Check live figures and official documents before any decision. This article is information only, not financial advice.
This article is for educational and informational purposes only and is not financial or investment advice. Crypto assets are high risk, their prices can be very volatile, and you can lose some or all of your money. Always do your own research and consider speaking with a licensed financial advisor before making investment decisions.
